U.S. Markets close in 2 hrs 5 mins
  • S&P 500

    -5.93 (-0.13%)
  • Dow 30

    +83.88 (+0.24%)
  • Nasdaq

    -131.22 (-0.86%)
  • Russell 2000

    -7.26 (-0.32%)
  • Gold

    +12.20 (+0.68%)

    +0.0003 (+0.0233%)
  • 10-Yr Bond

    -0.0190 (-1.13%)
  • Vix

    +0.53 (+3.53%)

    -0.0050 (-0.3601%)

    -0.5190 (-0.4553%)

    -1,947.36 (-3.11%)
  • CMC Crypto 200

    -56.92 (-3.79%)
  • FTSE 100

    +14.25 (+0.20%)
  • Nikkei 225

    +96.27 (+0.34%)

Is Abeona Therapeutics (ABEO) Stock a Solid Choice Right Now?

·2 min read

One stock that might be an intriguing choice for investors right now is Abeona Therapeutics Inc. ABEO. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 29 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Abeona Therapeutics Inc. Price and Consensus

Abeona Therapeutics Inc. Price and Consensus
Abeona Therapeutics Inc. Price and Consensus

Abeona Therapeutics Inc. price-consensus-chart | Abeona Therapeutics Inc. Quote

In fact, over the past month, current quarter estimates have narrowed from a loss of 27 cents per share to a loss 22 cents, while current year estimates have narrowed from a loss of $1.28 per share to a loss of $1.02. This has helped ABEO to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Abeona Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abeona Therapeutics Inc. (ABEO) : Free Stock Analysis Report
To read this article on Zacks.com click here.